Search Results - "Kuhn, J G"

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer by Rothenberg, M L, Eckardt, J R, Kuhn, J G, Burris, 3rd, H A, Nelson, J, Hilsenbeck, S G, Rodriguez, G I, Thurman, A M, Smith, L S, Eckhardt, S G, Weiss, G R, Elfring, G L, Rinaldi, D A, Schaaf, L J, Von Hoff, D D

“…To evaluate irinotecan (CPT-11; Yakult Honsha, Tokyo, Japan) in patients with metastatic colorectal carcinoma that had recurred or progressed following…”
Get more information

Cardiac arrest in private locations: different strategies are needed to improve outcome by Swor, Robert A., Jackson, R.E., Compton, S., Domeier, R., Zalenski, R., Honeycutt, L., Kuhn, G.J., Frederiksen, S., Pascual, R.G.

“…Background: A tremendous amount of public resources are focused on improving cardiac arrest (OHCA) survival in public places, yet most OHCAs occur in private…”
Get full text

Phase I and pharmacokinetic trial of weekly CPT-11 by Rothenberg, M L, Kuhn, J G, Burris, 3rd, H A, Nelson, J, Eckardt, J R, Tristan-Morales, M, Hilsenbeck, S G, Weiss, G R, Smith, L S, Rodriguez, G I

“…We conducted a phase I and pharmacokinetic trial of CPT-11 (irinotecan) to characterize the maximum-tolerated dose (MTD), toxicities, pharmacokinetic profile,…”
Get more information

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation by Rinaldi, D A, Burris, H A, Dorr, F A, Woodworth, J R, Kuhn, J G, Eckardt, J R, Rodriguez, G, Corso, S W, Fields, S M, Langley, C

“…To determine the toxicities, maximal-tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of LY231514, a novel thymidylate synthase…”
Get more information

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy by GRABINSKI, J. L, SMITH, L. S, POLLOCK, B. H, KUHN, J. G, CHISHOLM, G. B, DRENGLER, R, RODRIGUEZ, G. I, LANG, A. S, KALTER, S. P, GARNER, A. M, FICHTEL, L. M, HOLLSTEN, J

“…Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen. It has been shown that patients who…”
Get full text

Fluorouracil and the new oral fluorinated pyrimidines by Kuhn, JG

“…OBJECTIVE: To briefly review the biotransformation and bioavailability of fluorouracil (5-FU); discuss the effects of dihydropyrimidine dehydrogenase (DpD) on…”
Get full text

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report by Chang, S M, Kuhn, J G, Rizzo, J, Robins, H I, Schold, Jr, S C, Spence, A M, Berger, M S, Mehta, M P, Bozik, M E, Pollack, I, Gilbert, M, Fulton, D, Rankin, C, Malec, M, Prados, M D

“…To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. Patients were…”
Get more information

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation by RINALDI, D. A, KUHN, J. G, MASCORRO, D, ABRAHAMS, T, VON HOFF, D. D, BURRIS, H. A, DORR, F. A, RODRIGUEZ, G, ECKHARDT, S. G, JONES, S, WOODWORTH, J. R, BAKER, S, LANGLEY, C

“…To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of MTA, a novel antifolate compound which…”
Get full text

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro by Burris, 3rd, H A, Hanauske, A R, Johnson, R K, Marshall, M H, Kuhn, J G, Hilsenbeck, S G, Von Hoff, D D

“…Topotecan [(S)-9-dimethylaminomethyl(10-hydroxy-camptothecin), NSC 609699, SK&F 104864A], a semisynthetic analogue of the natural product camptothecin, is a…”
Get more information

Pharmacokinetics of itraconazole following oral administration to normal volunteers by HARDIN, T. C, GRAYBILL, J. R, FETCHICK, R, WOESTENBORGHS, R, RINALDI, M. G, KUHN, J. G

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks by Rothenberg, M. L., Kuhn, J. G., Schaaf, L. J., Rodriguez, G.I., Eckhardt, S. G., Villalona-Calero, M. A., Rinaldi, D. A., Hammond, L. A., Hodges, S., Sharma, A., Elfring, G. L., Petit, R. G., Locker, P. K., Miller, L. L., von Hoff, D. D.

“…Summary Objectives This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of…”
Get full text

A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies by HIDALGO, M, RODRIGUEZ, G, KUHN, J. G, BROWN, T, WEISS, G, MACGOVREN, J. P, VON HOFF, D. D, ROWINSKY, E. K

“…Acivicin is a glutamine analogue antimetabolite that inhibits several glutamate-dependent synthetic enzymes. Previous studies of this agent administered on a…”
Get full text

Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT) by Carr, M. E., Martin, E. J., Kuhn, J. G., Spiess, B. D.

“…Prothrombin activation requires the direct interplay of activated platelets and plasma clotting factors. Once formed, thrombin causes profound, irreversible…”
Get full text

Monitoring rFVIII prophylaxis dosing using global haemostasis assays by AL Hawaj, M. A., Martin, E. J., Venitz, J., Barrett, J. C., Kuhn, J. G., Nolte, M. E., Brophy, D. F.

“…Summary Secondary factor VIII (FVIII) prophylaxis converts severe haemophiliacs (FVIII:C < 1 IU dL−1) to a moderate phenotype (FVIII:C ≥ 1 IU dL−1), however,…”
Get full text

Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V‐stabilizing fab by Brophy, D. F., Martin, E. J., Mohammed, B. M., Barrett, J. C., Kuhn, J. G., Nolte, M. E., Wiinberg, B., Holmberg, H. L., Lund, J., Salbo, R., Waters, E. K.

“…Introduction The thrombomodulin (TM)/activated protein C (APC) system is a key regulator of haemostasis, limiting amplification and propagation of the formed…”
Get full text

Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection? by Lastrapes, K. K., Mohammed, B. M., Mazepa, M. A., Martin, E. J., Barrett, J. C., Massey, G. V., Kuhn, J. G., Nolte, M. E., Hoffman, M., Monroe, D. M., Brophy, D. F.

“…Introduction Coated platelets are a subpopulation of platelets that possess highly prothrombotic properties. Previous observational data suggest that bleeding…”
Get full text

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors by DRENGLER, R. L, KUHN, J. G, ELFRING, G. L, LOCKER, P. K, MILLER, L. L, VON HOFF, D. D, ROTHENBERG, M. L, SCHAAF, L. J, RODRIGUEZ, G. I, VILLALONA-CALERO, M. A, HAMMOND, L. A, STEPHENSON, J. A, HODGES, S, KRAYNAK, M. A, STATON, B. A

“…We conducted a phase I dose-escalation trial of orally administered irinotecan (CPT-11) to characterize the maximum-tolerated dose (MTD), dose-limiting…”
Get full text

9-cis-Retinoic Acid Suppresses Mammary Tumorigenesis in C3(1)-Simian Virus 40 T Antigen-transgenic Mice by WU, Kendall, KIM, Hee-Tae, GREEN, Jeff E, BROWN, Powel H, RODRIQUEZ, Jenny L, MUNOZ-MEDELLIN, Deborah, MOHSIN, Syed K, HILSENBECK, Susan G, LAMPH, William W, GOTTARDIS, Marco M, SHIRLEY, Michael A, KUHN, John G

“…Retinoids have been investigated as potential agents for the prevention and treatment of human cancers. These compounds play an important role in regulating…”
Get full text

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide by HAMMOND, L. A, ECKARDT, J. R, VON HOFF, D. D, ROWINSKY, E. K, GANAPATHI, R, BURRIS, H. A, RODRIGUEZ, G. A, ECKHARDT, S. G, ROTHENBERG, M. L, WEISS, G. R, KUHN, J. G, HODGES, S

“…Because topoisomerase (topo) I- and topo II-targeting agents exert their principal effects on the two major classes of enzymes involved in regulating DNA…”
Get full text

Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies by ECKHARDT, S. Gail, BAKER, Sharyn D, CLARK, Gary M, SMITH, Sheri L, MACDONALD, John R, SMITH, Charlotte, MOCZYGEMBA, Judy, WEITMAN, Steve, VON HOFF, Daniel D, ROWINSKY, Eric K, BRITTEN, Carolyn D, HIDALGO, Manuel, SIU, Lillian, HAMMOND, Lisa A, VILLALONA-CALERO, Miguel A, FELTON, Sally, DRENGLER, Ronald, KUHN, John G

“…To evaluate the toxicity and pharmacologic behavior of the novel mushroom-derived cytotoxin irofulven administered as a 5-minute intravenous (IV) infusion…”
Get full text